Qyuns Therapeutics Co., Ltd.
Building 1
Room 1310 No. 907 Yaocheng Avenue
Taizhou
China
86 523 8027 6311
https://www.qyuns.net
版塊: Healthcare
行業: Biotechnology
全職員工: 331
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Mr. Jiwan Qiu | GM, CEO & Chairman of the Board | 2.88M | 無 | 1972 |
| Mr. Yiliang Wu | Executive Director & Executive Deputy GM of Cellularforce | 1.56M | 無 | 1982 |
| Mr. Weidong Lin | Deputy GM & Executive Director | 1.94M | 無 | 1983 |
| Dr. Jianwei Li | Deputy GM & COO | 無 | 無 | 1961 |
| Mr. Shenglong Wu | Deputy GM & Chief Business Officer | 無 | 無 | 1974 |
| Ms. Min Fang | Deputy General Manager | 無 | 無 | 1976 |
| Mr. Yanbao Hu | Board Secretary & Joint Company Secretary | 無 | 無 | 1988 |
| Ms. King Yin Tang | Joint Company Secretary | 無 | 無 | 1987 |
描述
Qyuns Therapeutics Co., Ltd., a clinical-stage biotech company, focuses on biologic therapies for autoimmune and allergic diseases in the People's Republic of China. Its lead product candidates include QX002N, an interleukin (IL)-17A inhibitor for the treatment of ankylosing spondylitis (AS) and lupus nephritis (LN); and QX005N, a monoclonal antibody (mAb) blocking IL-4Ra to treat atopic dermatitis (AD), prurigo nodularis (PN), chronic rhinosinusitis with nasal polyps (CRSwNP), chronic spontaneous urticaria (CSU), asthma, and chronic obstructive pulmonary disease (COPD). The company also develops QX001S, an IL-12/IL-23p40 inhibitor for the treatment of psoriasis (Ps) and ulcerative colitis (UC)/Crohn's disease (CD); QX004N an IL-23p19 inhibitor to treat Ps and CD; QX006N, an IFNAR1-targeting mAb for the treatment of systemic lupus erythematosus (SLE); and QX008N, a humanized IgG1 mAb targeting thymic stromal lymphopoietin designed to treat moderate-to-severe asthma and COPD. In addition, it develops QX007N targeting IL-33 for the treatment of COPD and asthma; QX013N, a humanized IgG1 mAb targeting c-kit to treat CSU; and QX010N, an IL-31R inhibitor for the treatment of pruritus. The company engages in the research, development, and production of pharmaceutical products; and provision of technical consultation services. Qyuns Therapeutics Co., Ltd. was founded in 2015 and is headquartered in Taizhou, China.
公司管治
截至 無 止，Qyuns Therapeutics Co., Ltd. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。
